Report

QuickView: The power of the DARP side

With three blue-chip pharma partnerships funding more than eight programmes based on its proprietary DARPin therapeutic proteins, and CHF188m net cash following a recent IPO, Molecular Partners is in an enviable position. An announcement of the start of Phase III for abicipar, expected in Q215 from partner Allergan (acquired by Actavis), should allay investor concerns of any change in focus, although Molecular Partners now has sufficient cash to develop its substantial assets alone.
Underlying
Molecular Partners

Molecular Partners AG. Molecular Partners AG is a Switzerland-based company engaged in the pharmaceuticals industry. As a biopharmaceutical company, it is active in the research and development of proteins like DARPins (Designed Ankyrin Repeat Proteins), a new class of small proteins used for the development of medicine against diseases like cancer and sight-threating diseases, among others. The Company's pipeline is structured mainly through three areas: Ophthalmology, including the creation of therapies for renital diseases like wet age-related macular degeration (wet AMD) and diabetic macular edema (DME); Oncology, containing the development of DARPins against cancer, among others; and Immunology and other Indications, entailing DARPins against several targets important for the treatment of inflammatory and auto-immune diseases.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch